Scientists hunt for clues to personalize kidney disease treatment

NCT ID NCT07416942

First seen Feb 20, 2026 · Last updated Apr 30, 2026 · Updated 8 times

Summary

This study looks at stored blood and kidney samples from 120 people with membranous nephropathy (a kidney disease) to find biological markers that can predict who will respond to the drug rituximab. Researchers will analyze genetic, protein, and metabolic data to create a personalized medicine approach. Healthy volunteers also provide samples for comparison. The goal is to better match treatments to patients, not to test a new therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Research Centre for Rare Diseases Aldo e Cele Daccò

    Ranica, BG, 24020, Italy

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.